Summit Therapeutics Inc.
Every calculator, already run for SMMT
Open the full toolkit →You have the numbers on SMMT. Get the argument.
A written report on which of these readings actually decide the outcome for Summit Therapeutics Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
17 analysts covering SMMTAnalyst Price Target Disagreement for Summit Therapeutics Inc.
Wall Street's bull case implies +176% from the current price; the bear case implies -35%. A 211% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. I…
SMMT — frequently asked
Is SMMT a buy right now?
Wall Street's consensus rating on Summit Therapeutics Inc. is Buy across 17 analysts, with a mean price target of $28.47 (+88% vs. the current $15.12). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is SMMT's next earnings date?
Summit Therapeutics Inc. is next scheduled to report earnings around Oct 19, 2026. A full SMMT research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Summit Therapeutics Inc.?
Analysts covering Summit Therapeutics Inc. (SMMT) range from a bear-case target of $9.82 to a bull-case high of $41.66, with a mean consensus target of $28.47 across 13 analysts. The spread of $31.84 (211% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Summit Therapeutics Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Summit Therapeutics Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full SMMT research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Summit Therapeutics Inc., in minutes. 3 free reports included with every account — no credit card required.